Q2 2026 MindWalk Holdings Corp Earnings Call Transcript
Key Points
- MindWalk Holdings Corp (HYFT) reported a 54% year-over-year revenue growth, reaching $4.1 million for the second quarter.
- The company achieved a 94% increase in gross profit, amounting to $2.7 million, with a gross margin expansion to 65%.
- MindWalk successfully divested non-core wet lab operations in the Netherlands, generating approximately $14.3 million in net proceeds and strengthening the balance sheet.
- The company is advancing its GLP-1 and dengue vaccine programs using its proprietary LensAI and HYFT patterns, showcasing innovation in AI-driven drug discovery.
- MindWalk has established a Cayman Islands-based segregated portfolio structure to house and finance each AI-generated asset, allowing for targeted investment without diluting parent company equity.
- Operating expenses increased slightly to $5.4 million, reflecting higher R&D investment and expansion of general and administrative infrastructure.
- The company reported a net loss from continuing operations of $3.2 million, driven by divestiture-related impacts and a non-cash charge.
- Despite strong revenue growth, the company still faces challenges in achieving profitability, with an adjusted EBITDA loss of $2.4 million.
- MindWalk's strategic focus on AI and biologics may limit its ability to capitalize on broader market opportunities outside its niche.
- The company has not yet fully detailed the potential impacts or benefits of its Cayman segregated portfolio structure, leaving some investor uncertainty.
Good morning, ladies and gentlemen, and thank you for joining us today for MindWalk's second quarter fiscal 2026 earnings call. We appreciate your time and interest in MindWalk, formerly Immunoprecise Antibodies. Today's call will be led by our CEO, Dr. Jennifer Bath; and our CFO, Scott Areglado.
They will provide a review of our financial performance, strategic initiatives and key operational highlights for the second quarter. A copy of today's presentation along with our financial statements and MD&A is available on our website.
Before we begin, I would like to remind everyone that today's discussion will include forward-looking statements. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially.
Factors that could affect results include, among others, global political and economic conditions, changes in market dynamics, competitive development and other business risks. Unless otherwise noted, all financial figures discussed today are in Canadian dollars. These
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
